

Poland

Population 2016

38 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.48 (0.46–0.51)	1.3 (1.2–1.3)
Mortality (HIV+TB only)	0.027 (0.013–0.047)	0.07 (0.03–0.12)
Incidence (includes HIV+TB)	7.1 (6–8.2)	18 (16–21)
Incidence (HIV+TB only)	0.18 (0.099–0.28)	0.47 (0.26–0.73)
Incidence (MDR/RR-TB)**	0.09 (0.066–0.11)	0.24 (0.17–0.3)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.33 (0.28–0.37)	2 (1.7–2.3)	2.3 (2–2.7)
Males	0.37 (0.31–0.42)	4.4 (3.7–5)	4.7 (4–5.5)
Total	0.69 (0.59–0.8)	6.4 (5.4–7.3)	7.1 (6–8.2)

TB case notifications, 2016

Total cases notified	6 444
Total new and relapse	6 143
- % tested with rapid diagnostics at time of diagnosis	14%
- % with known HIV status	
- % pulmonary	95%
- % bacteriologically confirmed among pulmonary	75%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.07 (0.06–0.09)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			77 (56–98)
Estimated % of TB cases with MDR/RR-TB	0.83% (0.56–1.2)	4.4% (2.7–6.8)	
% notified tested for rifampicin resistance	65%	48%	4 193
MDR/RR-TB cases tested for resistance to second-line drugs			40
Laboratory-confirmed cases		MDR/RR-TB: 51, XDR-TB: 8	
Patients started on treatment ****		MDR/RR-TB: 46, XDR-TB: 8	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	53%	6 196
Previously treated cases, excluding relapse, registered in 2015	43%	189
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	18%	44
XDR-TB cases started on second-line treatment in 2014	20%	5

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	
------------------------------------	--

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



— New and relapse
— Retreatment, excluding relapse
— HIV-positive
— MDR/RR-TB
— XDR-TB

